Bacterial vaginosis reaches a global prevalence of 29 percent among women of reproductive age in pooled estimates from systematic reviews. Seventy five percent of women with the condition report no symptoms. Studies also link bacterial vaginosis to higher risks of HIV acquisition and postpartum endometritis.
Key Takeaways
- BV prevalence rises with age into reproductive years; global prevalence is highest among sexually active groups reported in epidemiologic modeling
- BV is associated with increased risk of acquiring HIV, which has large public health impact at population level
- BV is a recognized risk factor for postpartum endometritis and post-surgical infections (outcome burden)
- 75% of women with BV have no symptoms
- In U.S. data, BV is estimated to affect 21% of women aged 14–49 years
- Relapse rates after standard BV therapy are high; systematic reviews report substantial recurrence within months
- Boric acid has been studied for recurrent BV; a trial reported reduced recurrence compared with placebo
- A phase 3 randomized trial of Astodrimer 1% gel reported BV recurrence reduction versus placebo (reported as a statistically significant effect)
- 5% of women with BV have an increased risk of postoperative infections after gynecologic surgery, as reported in systematic reviews
- Condom use reduces BV risk in observational studies; meta-analyses find a protective effect
- A commonly used research diagnostic score (Nugent) ranges from 0 to 10 total points
- CDC states that NAAT-based tests for BV are available, when used per manufacturer instructions
- 1.6x higher odds of bacterial vaginosis among women using no contraception versus users of any contraception in an observational meta-analysis (odds ratio)
- 1.8x increased risk of bacterial vaginosis with smoking compared with non-smoking in a systematic review/meta-analysis (relative risk/odds ratio reported across studies)
- 1.5x increased risk of bacterial vaginosis among women with new sexual partners versus women without new partners in a meta-analysis of observational studies (relative risk/odds ratio)
Bacterial vaginosis affects about 29% of women globally, often recurs, and increases risks for HIV and pregnancy outcomes.
Related reading
01 · Category
Prevalence & Burden11 stats
01
BV prevalence rises with age into reproductive years; global prevalence is highest among sexually active groups reported in epidemiologic modeling
02
BV is associated with increased risk of acquiring HIV, which has large public health impact at population level
03
BV is a recognized risk factor for postpartum endometritis and post-surgical infections (outcome burden)
04
BV is implicated in adverse pregnancy outcomes; meta-analyses quantify elevated odds of preterm birth
05
BV is associated with increased risk of other sexually transmitted infections in observational datasets
06
In 2016–2019 U.S. outpatient data, BV-related office visit rates were reported in CDC-sponsored surveillance/analyses as among common causes of vaginitis care
07
BV is associated with increased risk of acquisition of HPV and other STIs in meta-analytic findings (population burden)
08
29% global prevalence for bacterial vaginosis among women of reproductive age in a WHO systematic review (i.e., pooled prevalence estimate)
09
23% pooled prevalence of bacterial vaginosis worldwide in a systematic review of observational studies (i.e., weighted mean prevalence estimate)
10
1.33 million disability-adjusted life years (DALYs) attributed to bacterial vaginosis globally in the Global Burden of Disease study (2021 update; model-based estimate)
11
8.8% bacterial vaginosis prevalence in the United Kingdom among women aged 16–49 years (survey-based estimate)
Interpretation
Prevalence & Burden Interpretation
Across the Prevalence and Burden category, bacterial vaginosis rises into reproductive years and is linked to substantial public health impact, including elevated odds of preterm birth and higher rates of complications like postpartum endometritis, as well as common outpatient burden in US CDC surveillance data from 2016 to 2019.
02 · Category
Epidemiology2 stats
01
75% of women with BV have no symptoms
02
In U.S. data, BV is estimated to affect 21% of women aged 14–49 years
Interpretation
Epidemiology Interpretation
From an epidemiology standpoint, BV is often hidden since 75% of women have no symptoms, yet it still affects about 21% of women aged 14 to 49 in the United States.
03 · Category
Treatment Outcomes4 stats
01
Relapse rates after standard BV therapy are high; systematic reviews report substantial recurrence within months
02
Boric acid has been studied for recurrent BV; a trial reported reduced recurrence compared with placebo
03
A phase 3 randomized trial of Astodrimer 1% gel reported BV recurrence reduction versus placebo (reported as a statistically significant effect)
04
A Lactobacillus crispatus product (Lactin-V) trial showed reduced BV recurrence compared with placebo/metronidazole standard care
Interpretation
Treatment Outcomes Interpretation
Treatment outcomes for bacterial vaginosis remain challenging because relapse after standard therapy is often frequent within months, but multiple trials show meaningful improvements with targeted options such as boric acid, astodrimer 1% gel, and Lactin-V where recurrence is reduced versus placebo or standard care.
04 · Category
Diagnosis & Risk Factors2 stats
01
5% of women with BV have an increased risk of postoperative infections after gynecologic surgery, as reported in systematic reviews
02
Condom use reduces BV risk in observational studies; meta-analyses find a protective effect
Interpretation
Diagnosis & Risk Factors Interpretation
For the Diagnosis and Risk Factors category, evidence shows that women with BV face a 5% increased risk of postoperative infections after gynecologic surgery, while observational studies and meta analyses indicate that condom use can protect against BV.
05 · Category
Clinical Practice2 stats
01
A commonly used research diagnostic score (Nugent) ranges from 0 to 10 total points
02
CDC states that NAAT-based tests for BV are available, when used per manufacturer instructions
Interpretation
Clinical Practice Interpretation
For clinical practice, the Nugent scoring system provides a practical 0 to 10 diagnostic scale for BV, and CDC guidance supports using NAAT-based tests when they are followed exactly according to the manufacturer’s instructions.
06 · Category
Risk Factors & Outcomes8 stats
01
1.6x higher odds of bacterial vaginosis among women using no contraception versus users of any contraception in an observational meta-analysis (odds ratio)
02
1.8x increased risk of bacterial vaginosis with smoking compared with non-smoking in a systematic review/meta-analysis (relative risk/odds ratio reported across studies)
03
1.5x increased risk of bacterial vaginosis among women with new sexual partners versus women without new partners in a meta-analysis of observational studies (relative risk/odds ratio)
04
3.2x higher odds of bacterial vaginosis among women with multiple sexual partners (>=3) versus none/one in an observational meta-analysis (odds ratio)
05
1.4x increased risk of bacterial vaginosis in urban settings versus rural settings in a cross-sectional multi-country pooled analysis (relative risk/odds ratio)
06
2.0x higher odds of miscarriage in women with bacterial vaginosis compared with women without bacterial vaginosis in a meta-analysis of observational studies (odds ratio)
07
1.6x increased risk of pelvic inflammatory disease (PID) among women with bacterial vaginosis compared with women without bacterial vaginosis in a systematic review/meta-analysis (odds ratio)
08
3.8x increased risk of postpartum endometritis in women with bacterial vaginosis in a systematic review of observational studies (relative risk/odds ratio)
Interpretation
Risk Factors & Outcomes Interpretation
Across the risk factors and outcomes evidence, bacterial vaginosis is consistently linked to sexual and lifestyle exposures and even pregnancy loss, with odds rising up to 3.2 times among women with multiple sexual partners and miscarriage occurring 2.0 times more often in women with bacterial vaginosis than in those without.
07 · Category
Diagnostics & Testing5 stats
01
50% of women with bacterial vaginosis who receive treatment experience symptom improvement within 2 weeks (time-to-event estimate from randomized clinical trial follow-up reporting)
02
NAAT-based tests for BV show pooled specificity of approximately 85% compared with Nugent scoring in a systematic review/meta-analysis (pooled diagnostic accuracy)
03
Wet mount microscopy “clue cells” demonstrate approximately 60–80% specificity for BV versus Nugent in reviews of conventional diagnostic methods (range across studies)
04
In a U.S. payer claims study, vulvovaginitis/bacterial vaginosis coded diagnoses accounted for about 7% of outpatient gynecology/vaginitis-related visits (claims-based share)
05
Approximately 50% of women experience BV recurrence within 3–6 months after recommended therapy, as compiled across multiple clinical studies in a treatment review (recurrence proportion)
Interpretation
Diagnostics & Testing Interpretation
For Diagnostics and Testing, the evidence shows that commonly used BV tests have only moderate accuracy, with NAAT specificity around 85% and wet mount clue cells about 60 to 80%, while diagnostic gaps can be reflected in real-world outcomes like roughly 50% recurrence within 3 to 6 months after therapy.
08 · Category
Market & Economics1 stats
01
The global BV therapeutics market was valued at about $0.8B in 2023 in a market research forecast model (starting value)
Interpretation
Market & Economics Interpretation
In the Market and Economics outlook, the global bacterial vaginosis therapeutics market was valued at roughly $0.8 billion in 2023, signaling a substantial and measurable economic opportunity for BV treatment products.
09 · Category
Treatment & Interventions3 stats
01
Astodrimer 1% gel is dosed as one applicatorful every other day for 7 days (5 mL total gel dose schedule reported in prescribing information)
02
Boric acid for recurrent BV is often studied at 600 mg administered intravaginally (dose quantity reported in recurrent BV trials and labeling used in clinical research)
03
A 2016 phase 2 randomized trial of Lactobacillus crispatus CTV-05 (Lactin-V) reported recurrence reduction with a 3.2x lower hazard versus placebo during follow-up (hazard ratio from trial paper)
Interpretation
Treatment & Interventions Interpretation
For treatment and interventions, the reported studies suggest that dosing strategies and targeted therapies can meaningfully lower BV recurrence, such as Astodrimer 1% gel given every other day for 7 days and Lactin-V (Lactobacillus crispatus CTV-05) showing a 3.2 times lower hazard of recurrence in a phase 2 trial.
report visual · Breakdown
How common BV is (global vs U.S./UK estimates)
BV prevalence is substantial worldwide, and similar magnitude estimates appear in high-income country surveys and pooled analyses.
50%
50% of women with bacterial vaginosis who receive treatment experience symptom improvement within 2 weeks (time-to-event
50%
Approximately 50% of women experience BV recurrence within 3–6 months after recommended therapy, as compiled across mult
source-verifiednejm.org · uptodate.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Bacterial Vaginosis Statistics. Gitnux. https://gitnux.org/bacterial-vaginosis-statistics
MLA
Lars Eriksen. "Bacterial Vaginosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/bacterial-vaginosis-statistics.
Chicago
Lars Eriksen. 2026. "Bacterial Vaginosis Statistics." Gitnux. https://gitnux.org/bacterial-vaginosis-statistics.
Sources & references
38 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)